ADCs for B-cell malignancies. ADCs with US Food and Drug Administration–approved indication for B-cell malignancies (boxed) compared with ABBV-319, as reported by Chang et al. The product names are listed in bold, the targeting mAb or, in the case of moxetumomab pasudotox, the targeting binding fragment below the product name, and on the bottom, the linked payload. Payloads include anti-microtubule payloads (blue shading) and genotoxins (yellow shading). Af., afucosylated; GRM, glucocorticoid receptor modulator; MMAE, monomethyl auristatin E; SG3199, pyrrolobenzodiazepine dimer. Created with BioRender.com.